About Us
Retinal Consultants of Arizona (RCA) was established in 1980 in central Phoenix. Since then, we have grown to include 32 locations throughout Arizona, providing improved access to the highest quality medical care.
We are proud to have become Arizona’s largest and most experienced ophthalmology practice focused specifically on the diagnosis and management of the retina and vitreous. We hope our website will provide answers to some of your questions about the care and services we provide. You will find an overview of RCA’s doctors and useful patient information, as well as information regarding ongoing research and educational activities.
Although RCA has grown over the years to better serve our communities with improved access to the latest technology and treatment, we still commit ourselves to the importance of compassionate, individualized care. We look forward to listening to you and explaining your condition while providing a partnership to achieve the best possible outcome.
Why RCA
All of our physicians are Board Certified by the American Board of Ophthalmology, with additional subspecialty training in the diagnosis and treatment of diseases affecting the retina, vitreous, and macula. Our doctors have trained at world-renowned facilities, but more importantly, we strive to make your experience at RCA a positive one. We understand that an urgent visit to the doctor’s office can be stressful, and we will do everything possible to work with you to provide a compassionate explanation of your condition and treatment options. We value your feedback and we always strive to improve your visit with us.
We understand your time is valuable and we have many locations across Arizona to better serve your needs. We will make every effort to make your experience at RCA both convenient and efficient.
Unfortunately, there are many medical conditions that do not have a “cure.” Although we provide the latest technology available to treat retinal disorders, we are actively involved in multiple clinical research trials in hopes of expanding our treatment options for our patients. RCA physicians contribute to the advancement of new therapies by participating in clinical research studies, which represent the most advanced research being conducted in ophthalmology today. We are proud of the fact that RCA’s Retinal Research Institute is one of the busiest and largest retina-only research organizations in the country. Often, our clinical trials provide patients with a treatment option for diseases that don’t have any other available therapies.
If you have any questions or need additional information, please don’t hesitate to contact us by email or call.
Learn More about RCA
RCA Aviation
In order to provide all Arizonans with the highest quality retina services, RCA Aviation has invested in the purchase of two planes to transport staff, equipment and medicines to its locations outside of Phoenix on a daily basis.
Philanthropy
Giving back to causes that support our patients and advancements in vision care is an important part of what we do. Learn more about foundations and causes that we support.
Innovation & Technology
We are proud to feature some of the latest technologies in the industry today from companies around the world leading the ophthalmic industry in innovation and technology.
News
Keep up with Retinal Consultants of Arizona! Take a look at what is going on at RCA in our news updates.
Schedule an Appointment
We’re here to help. If you’re noticing changes in your vision or are looking for treatment for an existing retinal condition, schedule an appointment with our retinal specialists.
(602) 222-2221
Follow Us On Social
Pravin U. Dugel, MD: Conversations in Age-Related Macular Degeneration
/ Uncategorized /by retinalconsultantsNeovascular AMD Pravin U. Dugel, MD What up-and-coming therapies for wet AMD are you most excited about and why? The therapies currently being investigated for neovascular age-related macular degeneration (nvAMD) can be stratified into 3 silos: better short-term efficacy, better long-term efficacy, and increased durability. The majority of drugs in the pipeline have focused on […]
Pravin U. Dugel, MD: Opthea First-in-Human Clinical Data for OPT-302 in wet AMD Published in Leading Ophthalmic Journal
/ Uncategorized /by retinalconsultantsMelbourne, Australia; 29 October 2019 – Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases, today announced the publication of positive data from the first-in-human clinical trial of OPT-302, in patients with neovascular (wet) age-related macular degeneration (wet AMD). The successful trial results were published today in Ophthalmology Retina, […]